Lupin receives USFDA approval for Fesoterodine Fumarate extended-release tablets; Stock up 1%

9 Jan 2023 , 12:43 PM

Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg,

As per the regulatory filing, Fesoterodine Fumarate Extended-Release Tablets is launched to market a generic equivalent of Toviaz Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc. The product will be manufactured at Lupin’s facility in Goa, India.

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).

At around 12:45 PM, Lupin was trading at Rs754.95 per share higher by 1.02% on the BSE.

For feedback and suggestions, write to us at [e-mail]